Category: Biotechnology
Biotechnology market research reports by Global Markets Direct
-
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa ... Read More
-
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastroin ... Read More
-
Neurofibromatoses Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neurofibromatoses Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Drugs In Development, 2022, provides an overview of the Neuro ... Read More
-
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Drugs In Development, 2022, provides an overview of the Polyc ... Read More
-
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides an overvie ... Read More
-
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – C-C chemokine receptor type 4 is a protein encoded by the CCR4 gen ... Read More
-
Calcitonin Gene Related Peptide (CGRP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Calcitonin Gene Related Peptide (CGRP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Calcitonin Gene Related Peptide (CGRP) – Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exis ... Read More
-
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Nicotinamide Phosp ... Read More
-
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic ... Read More
-
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes clos ... Read More
-
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to ... Read More
-
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or ... Read More
-
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Toll Like Receptor 8 - Drugs In Development, 2022'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target ... Read More
-
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) pipeline Target constitutes close to 12 ... Read More
-
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Bromodomain Containing Protein 3 - Drugs In Development, 2022'; Bromodomain Con ... Read More
-
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Alpha L-Iduronidase - Drugs In Development, 2022'; Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeli ... Read More
-
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 35 molecules ... Read More
-
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 53 molecul ... Read More
-
Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Drugs in Development by Stages, Target, MoA, RoA, Mol ... Read More
-
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamida ... Read More
-
Human Cytomegalovirus Envelope Glycoprotein B (gB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Human Cytomegalovirus Envelope Glycoprotein B (gB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 mo ... Read More
-
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Serine Protein Kinase A ... Read More
-
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 8 molecules. Out of ... Read More
-
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Histone Deacetylase 4 - Drugs In Development, 2022'; Histone Deacetylas ... Read More
-
Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It controls host immune response against p ... Read More
Research Assistance
